Cantex Pharmaceuticals

About Cantex Pharmaceuticals

Cantex Pharmaceuticals, Inc. is a clinical stage pharmaceutical company dedicated to developing and commercializing proprietary pharmaceuticals aimed at improving the treatment of cancer and other life-threatening illnesses. The company's lead product, DSTAT (formerly known as CX-01), is currently under investigation for the treatment of acute lung injury (ALI) in COVID-19 patients and acute myeloid leukemia (AML). Cantex operates in the biopharmaceutical market, focusing on innovative therapies that address unmet medical needs. The company primarily serves healthcare providers, hospitals, and research institutions. Its business model revolves around the development, clinical testing, and eventual commercialization of its pharmaceutical products. Revenue is generated through licensing agreements, partnerships, and potential future sales of approved drugs. Cantex's strategic approach includes collaborating with other pharmaceutical companies, such as Chimerix, which is the exclusive licensee of DSTAT and has initiated a Phase 2/3 study for its use in severe COVID-19 cases.